[Tend to second-line therapy in lung cancer]

Gan To Kagaku Ryoho. 2015 Apr;42(4):416-20.
[Article in Japanese]

Abstract

Second-line chemotherapy has been established for non-small-cell lung cancer(NSCLC)and sensitive relapsed small cell lung cancer(SCLC).Molecular targeted drugs, such as EGFR- and ALK-inhibitors, have improved survival outcome remarkably in patients with NSCLC harboring EGFR mutations or EML4-ALK fusion proteins.In addition, targeted drugs that may overcome T790M-mediated EGFR-TKI resistance have been developed, and the development of future therapeutic strategies is anticipated.On the other hand, molecular targeted drugs against SCLC have not yet been developed.

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Small Cell / drug therapy*
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mutation
  • Recurrence

Substances

  • Antineoplastic Agents
  • EGFR protein, human
  • ErbB Receptors